Ultra Wellness Utah

GLP-3

Triple-action GLP-1/GIP/glucagon receptor agonist studied in Phase 3 clinical trials for metabolic support.

About this page

GLP-3 is a next-generation triple-receptor research peptide targeting GLP-1, GIP, and glucagon receptors simultaneously. It is studied in metabolic-health and body-composition research.

Category: Weight Management & Metabolic Health. View the linked research sources and related educational resources for additional context.

Frequently asked questions

How does GLP-3 differ from Tirzepatide in research?

GLP-3 is studied with glucagon receptor agonism in addition to the GLP-1/GIP mechanisms studied in Tirzepatide. Head-to-head research comparisons remain ongoing.

What research timelines have been studied?

Phase 2 data reported outcomes at 12, 24, and 48 weeks. Phase 3 trials are evaluating 68-week endpoints.

What other compounds are studied alongside GLP-3?

Research protocols examine GLP-3 alongside lifestyle interventions and metabolic compounds including NAD+ precursors.